E5 蛋白:人类乳头瘤病毒阳性头癌的关键参与者 发病因和治疗耐药性
Vanessa Emanuelle Pereira Santos1, Bianca de França São Marcos1, Pedro Henrique Bezerra Fontes1
1Laboratory of Molecular Studies and Experimental Therapy, Department of Genetics, Federal University of Pernambuco, Av. Prof. Moraes Rego, 1235., 50670-901 Pernambuco, Brazil.
人类乳头瘤病毒 (HPV) 蛋白E5可能导致头癌 (HNC) 的化疗耐药性. 准HPV E5对新型HNC疗法有希望,改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 分子生物学分子生物学
背景情况:
- 头癌 (HNC) 是一个重要的全球健康问题,生存率很低.
- 虽然吸烟和酒精是主要的危险因素,但人类乳头瘤病毒 (HPV) 感染越来越被认可,特别是在口腔瘤中.
- 阳性HPV的HNC患者通常有更好的预后,但往往会对化疗产生耐药性.
研究的目的:
- 审查HPV上蛋白E5在头部和部癌症发生中的作用.
- 探索针对HPV E5的潜力,用于HNC的新疗法策略.
- 讨论HPV E5之间的联系,免疫逃避和化疗耐药性.
主要方法:
- 关于HPVcoproteins和HNC的研究的文献综述.
- 对将HPV E5与瘤微环境调节联系起来的数据的分析.
- 检查HPV相关化疗耐药性背后的机制.
主要成果:
- HPV 型蛋白 E5,E6 和 E7 都有助于 HNC 的发展.
- HPV E5与免疫规避和改变瘤微环境有关.
- 这些E5介导的效应似乎与对化疗剂的耐药性相关.
结论:
- HPV E5在头癌发生和治疗耐药性方面起着至关重要的作用.
- 针对HPV E5代表了HPV阳性HNC的潜在治疗途径.
- 对HPV E5机制的进一步研究可能会导致改善HNC治疗策略.
更多相关视频
06:57Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
07:43Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
Published on: July 29, 2017
相关概念视频
Mitogens and the Cell Cycle
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mechanisms of Retrovirus-induced Cancers
Treatment Resistant Cancers
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
